Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 2, 2020

Carag receives approval for transcatheter septal occluder study in US

Swiss medical device development company Carag has received the US Food and Drug Administration (FDA) investigational device exemption (IDE) approval for its Carag Bioresorbable Septal Occluder (CBSO).

Swiss medical device development company Carag has received the US Food and Drug Administration (FDA) investigational device exemption (IDE) approval for its Carag Bioresorbable Septal Occluder (CBSO).

The CE-marked CBSO is a transcatheter septal occluder with a bioresorbable, metal-free framework.

The US clinical study for the device will enrol 250 patients in a staged study approach. The prospective, multi-centre study will evaluate the safety and efficacy of the CBSO in patients with clinically significant atrial septal defects (ASD).

Transcatheter implants with a metal framework, currently used for the treatment of ASD, are said to permanently clamp the septum.

The long-term presence of metal in the heart can cause severe complications, including erosion, arrhythmia and thrombus formation. In addition, such devices also limit the scope for future heart interventions, requiring septum crossing.

Carag CEO Jérôme Bernhard said: “We designed the CBSO to achieve a more natural intact septum by eliminating the metal framework, which has no purpose once the septum is healed.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

“Our novel approach enables pediatric and adult cardiologists to perform transcatheter septal occlusions today that will not undermine future left-sided interventional procedures, requiring transseptal access.”

The company expects to start the trial enrolment later this year.

Patients with ASD have an opening in the septum between the atria, allowing blood to return from the left to the right side of the heart. The excess of blood in the right ventricle and lungs can lead to enlargement of the right ventricle, shortness of breath, fatigue and palpitations.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU